

Number 637 • September 2016

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Lorazepam 0.5 mg Sublingual Tablet (DIN 02410745) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 17, 2016**.

LORAZEPAM

0.5 MG SUBLINGUAL TABLET

00002410745	APO-LORAZEPAM	ΑΡΧ	\$ 0.0875
00002041456	ATIVAN	PFI	\$ 0.1147

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Lorazepam 1 mg Sublingual Tablet (DIN 02410753) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 17, 2016.**

LORAZEPAM

1 MG SUBLINGUAL TABLET

00002410753	APO-LORAZEPAM	ΑΡΧ	\$ 0.1100
00002041464	ATIVAN	PFI	\$ 0.1442

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit https://www.ab.bluecross.ca/providers/pharmacy-home.php**



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.637 2016/09

